Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin Corporation plc (NASDAQ:AMRN) announced plans to enhance promotion and education for VASCEPA® (icosapent ethyl), targeting high-risk cardiovascular patients. Following its FDA approval in December 2019, awareness is crucial as many healthcare providers and patients are unaware of VASCEPA's unique benefits. Amarin intends to restore $80 million in marketing efforts and resume face-to-face interactions with healthcare providers by late June 2020. Prescription growth has slowed due to COVID-19, but patient visits are increasing. The company also anticipates potential impacts from ongoing patent litigation concerning generic versions of VASCEPA.
Amarin Corporation plc (NASDAQ:AMRN) is supporting a clinical trial to examine the effects of icosapent ethyl (IPE) on inflammatory biomarkers in COVID-19 patients. Sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group, the trial is led by Dr. Subodh Verma and Dr. Deepak L. Bhatt. The primary endpoint is the impact of VASCEPA on high-sensitivity C-reactive protein levels after 14 days. Given the potential risks of COVID-19 in cardiovascular patients, VASCEPA may offer beneficial effects. The study aims to assess various outcomes and may lead to larger studies if positive results are observed.
Amarin Corporation (NASDAQ:AMRN) announced new findings from the REDUCE-IT study, revealing a 34% reduction in first coronary revascularizations and a 36% reduction in total revascularizations with VASCEPA (icosapent ethyl) compared to placebo. The study indicated significant decreases in urgent, emergent, and elective procedures. Substantial reductions were also observed in percutaneous coronary intervention (32%) and coronary artery bypass grafting (39%). These results emphasize VASCEPA's potential to positively impact cardiovascular care for patients with elevated triglycerides.
Summary not available.
Summary not available.